Table of Contents
- Overview of the trials
- Conditions being studied
- Trial design, phases, and study groups
- Main endpoints being measured
- Who the trials are for
- What is being tested in the treatment plans
- Key patient points
Overview of the trials
The source data shows several clinical trials that include Vindesine Sulfate as one part of a larger cancer treatment plan.[1][2][3] These studies are being done in children and adolescents, mainly for blood cancers and neuroblastoma.[1][4]
Most of the trials are Phase 3 studies, which means they compare treatment strategies in larger groups of patients.[1][4] One study is Phase 4, which usually looks at treatment use after earlier testing.[2]
Conditions being studied
The trials cover several different conditions. These include low and intermediate risk neuroblastoma, acute lymphoblastic leukemia, lymphoblastic lymphoma, mature aggressive B-cell lymphoma and leukemia, and relapsed ALL.[1][2][3][4][5][6][7]
Several studies focus on specific risk groups, such as early high-risk, high-risk, intermediate risk, or relapsed disease.[3][5][6][7] This means the trials are not all for the same type of patient, even when the cancer diagnosis is similar.
Trial design, phases, and study groups
All of the listed studies are interventional, which means the researchers assign treatment plans and then measure the results.[1][2][3][4][5][6][7] Several studies use randomization, where patients are put by chance into different treatment groups.[3][5][6]
In the neuroblastoma study, the goal is to use gene expression-based risk stratification to guide treatment intensity.[1] In the leukemia and lymphoma studies, the trials compare standard therapy with added or changed treatment blocks, including immunotherapy or intensified chemotherapy in some groups.[3][4][5][6][7]
Some studies include special subgroups such as children with confirmed activation of the JAK/STAT pathway, patients with minimal residual disease, or patients with central nervous system relapse.[2][5][6][7] These details show that the trials are designed for very specific patient groups.
Main endpoints being measured
The most common main endpoint is event-free survival (EFS), which measures how long patients stay free from major events such as relapse, progression, death, or a second cancer.[1][3][4][6][7]
Some studies use disease-free survival (DFS), which looks at how long the cancer stays away after treatment.[3][5][7] Other important endpoints include the rate of MRD-negative results, meaning no minimal residual disease is found, and the rate of treatment-related side effects or toxicities.[2][3]
One lymphoma study also measures immune reconstitution, which means recovery of the immune system, especially B-cell counts.[4] Another study focuses on the cumulative incidence of central nervous system relapse, which is the chance of cancer returning in the brain or spinal fluid area.[5]
Who the trials are for
The target populations are mainly children and adolescents with cancer.[1][4][5][6] Some studies focus on newly diagnosed patients, while others focus on relapsed disease or patients who have not responded well to earlier treatment.[1][2][3][7]
Several trials also divide patients by risk level, such as low risk, intermediate risk, high risk, or very high risk.[1][3][6] This helps researchers test whether a stronger or gentler treatment plan is best for each group.
What is being tested in the treatment plans
In the source data, Vindesine Sulfate is always used with other medicines, not alone.[1][3][4][5][6][7] The trials compare different treatment strategies such as standard chemotherapy, intensified chemotherapy, immunotherapy, or treatment guided by risk testing.[1][3][4][5][6][7]
Examples from the source data include studies that test whether adding bortezomib, blinatumomab, rituximab, or other treatment changes can improve outcomes in selected patient groups.[3][4][5][6][7] The neuroblastoma trial also studies whether treatment can be adjusted based on gene expression risk grouping.[1]
Key patient points
These trials are focused on finding better cancer treatment plans for young patients, especially by matching treatment intensity to risk level and response.[1][3][6] The main question is not just whether treatment works, but whether it can work better, with fewer bad outcomes or less treatment burden in some groups.[2][3][4]
Because the studies are different in diagnosis, risk group, and treatment plan, eligibility depends on the exact trial.[1][2][3][4][5][6][7] The source data shows that Vindesine Sulfate is part of broader research efforts in pediatric oncology, especially in leukemia and lymphoma protocols.[3][4][5][6][7]
